ArticleGeroScience2026
PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The d emographic shift toward an older population is accelerating the prevalence of age-related diseases. Precision geromedicine represents a paradigm shift in targeting the biological processes of ageing to optimise health and healthspan, which likely requires multimodal tailored interventions. PROMETHEUS, as part of the XPRIZE healthspan semi-finalist competition, is an 8-week feasibility and exploratory study including 20 middle-aged-to-older participants who received a multimodal intervention comprising fundamental and augmented interventions. The fundamental interventions include sleep and dietary recommendations; supplementation with whey protein, creatine, and fucoidan; supervised exercise with an exergaming component (dual-task cognitive-physical training); motivational interviewing; and cognitive behavioural therapy. The augmented intervention is further personalised based on predefined gerotypes, reflecting individual ageing patterns beyond chronological age. At baseline, urolithin A, nicotinamide mononucleotide, and/or multivitamin-multimineral were prescribed to participants based on their muscle mass, VO
Indexed as
Identifiers
42393428What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.